Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis

Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum

(2020) Divyanshu Dubey et al.   ANNALS OF NEUROLOGY

Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study

(2020) Frank B. Cortazar et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

(2020) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

(2020) Sarah Abou Alaiwi et al.   Journal for ImmunoTherapy of Cancer

Immune-Related Adverse Events (irAEs): Diagnosis, Management, and Clinical Pearls

(2020) Eli P. Darnell et al.   Current Oncology Reports

Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer

(2020) Charles Dolladille et al.   JAMA Oncology

Evaluation of the Safety and Efficacy of Immunotherapy Rechallenge in Patients With Renal Cell Carcinoma

(2020) Praful Ravi et al.   JAMA Oncology

Safety of Immunotherapy Rechallenge After Immune-related Adverse Events in Patients With Advanced Cancer

(2020) Adi Kartolo et al.   JOURNAL OF IMMUNOTHERAPY

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Safety of Nivolumab plus Low‐Dose Ipilimumab in Previously Treated Microsatellite Instability‐High/Mismatch Repair‐Deficient Metastatic Colorectal Cancer

(2019) Michael A. Morse et al.   ONCOLOGIST

Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies

(2019) KOHEI FUJITA et al.   ANTICANCER RESEARCH

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

(2019) Hamzah Abu-Sbeih et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer

(2019) Atsuto Mouri et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors

(2019) Ethan D. Miller et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Recurrence of Immune-Mediated Colitis Upon Immune Checkpoint Inhibitor Resumption: Does Time Matter?

(2019) Julie Delyon et al.   JOURNAL OF CLINICAL ONCOLOGY

Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases

(2018) Kohei Fujita et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Safety and Efficacy of Retreating with Immunotherapy After Immune-Related Adverse Events in Patients with NSCLC

(2018) Fernando Costa Santini et al.   Cancer Immunology Research

Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer

(2018) Maiko Niki et al.   Oncotarget

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

(2018)   Journal for ImmunoTherapy of Cancer

Programmed cell death protein-1 (PD-1) inhibitor therapy in patients with advanced melanoma and preexisting autoimmunity or ipilimumab-triggered autoimmunity

(2017) Ralf Gutzmer et al.   EUROPEAN JOURNAL OF CANCER

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

(2017) Jarushka Naidoo et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy

(2017) Reyhan Amode et al.   MELANOMA RESEARCH

Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract

(2017) Michael Dougan   Frontiers in Immunology

Corticosteroids for the management of immune-related adverse events in patients receiving checkpoint inhibitors

(2017) Kiersten J Williams et al.   JOURNAL OF ONCOLOGY PHARMACY PRACTICE

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab

(2016) A. M. Menzies et al.   ANNALS OF ONCOLOGY

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

(2016) Celine Boutros et al.   Nature Reviews Clinical Oncology

Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota

(2015) M. Vetizou et al.   SCIENCE

Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies

(2014) C. Lebbe et al.   ANNALS OF ONCOLOGY

Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control

(2013) C. Robert et al.   CLINICAL CANCER RESEARCH

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

(2010) Andreas Stang   EUROPEAN JOURNAL OF EPIDEMIOLOGY

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE